Biogen Delves Deeper Into Biosimilars With Tocilizumab Partnership
Signs Agreement With China’s Bio-Thera Solutions Worth Over $30m
Biogen has broken new ground in its biosimilar endeavors, expanding beyond its partnership with its part-owned Samsung Bioepis company by agreeing a deal for rights to Bio-Thera Solutions’ BAT1806 biosimilar Actemra/RoActemra (tocilizumab) candidate.
You may also be interested in...
Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”
Celltrion has provided the latest update on progress for its CT-P47 proposed tocilizumab biosimilar, with Phase III trials set to begin for its rival to Actemra/RoActemra.
Roche gave small insight into its expectations around biosimilar competition for its Actemra/RoActemra (tocilizumab) treatment for inflammatory diseases. Extraordinary demand for the biologic led sales to skyrocket by 143% in the third quarter and caused supply constraints for the originator.